Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs ADU 623 (Primary)
- Indications Astrocytoma
- Focus Adverse reactions; First in man
- Sponsors Aduro BioTech
- 13 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2018.
- 13 Jun 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2017.
- 09 Nov 2015 Data presented at the Society for Immunotherapy of Cancer Annual Meeting 2015, according to an Aduro BioTech media release.